[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Stryker Instruments\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100291373","mild-percutaneous-image-guided-lumbar-decompression-a-medicare-claims-study-100291373",false,"NCT03072927","MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study","Inclusion Criteria:\n\n* Medicare beneficiaries receiving MILD or interspinous process decompression\n* Diagnosis of LSS with NC\n\nExclusion Criteria:\n\n* Patients that have received a laminectomy, laminotomy, fusion, interspinous process decompression, or MILD in the lumbar region during the 12 months prior to the index date","ALL","18 Years",{"count":18,"type":19},8000,"ESTIMATED","OBSERVATIONAL","This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by the sponsor.",[23],"Lumbar Spinal Stenosis",[23,25,26,27,28],"Interspinous process decompression","MILD","Medicare","Medicare Advantage","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2017-03-10",{"date":37,"type":19},"2026-12",{"name":39,"class":40},"Stryker Instruments","INDUSTRY",2326,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100623107","a-prospective-cohort-study-of-basivertebral-nerve-ablation-using-the-stryker-optablate-bvn-system-for-the-treatment-of-vertebrogenic-low-back-pain-100623107","NCT07392333","A Prospective Cohort Study of Basivertebral Nerve Ablation Using the Stryker OptaBlate BVN System for the Treatment of Vertebrogenic Low Back Pain","OptaBlate BVN","Inclusion Criteria:\n\n* Patient scheduled for treatment with the OptaBlate BVN System in accordance with the device IFU and willing to participate in the clinical investigation, undergo study procedure, engage in follow-up, able to read, write, speak, and understand English, and able to provide written informed consent.\n\nExclusion Criteria:\n\n* The patient meets one or more contraindications as defined in the locally applicable IFU\n* Spinal fracture or history of spinal trauma at index levels\n* Previous lumbar fusion at any level\n* Prior basivertebral nerve ablation at the target levels\n* Vertebral cancer, spinal metastasis or Tumor-related vertebral fractures\n* History of Osteoporotic vertebral fractures\n* Spine interventions, including epidural steroid injections within 30 days\n* BMI \\> 40 kg\u002Fm²\n* Symptomatic spinal stenosis\n* Radicular pain or leg pain greater than back pain\n* Pregnancy or planning pregnancy during study period\n* Enrollment in another interventional clinical trial\n* Contraindication to MRI\n* Life expectancy of less than 12 months","22 Years",{"count":51,"type":19},25,"The goal of this observational study is to evaluate patient outcomes following treatment of vertebrogenic low back pain using the Stryker OptaBlate BVN System. Patients treated in accordance with the device IFU as part of routine clinical care and who consent to participate will be followed for 12 months after the procedure to assess treatment outcomes.",[54,55],"Verteborgenic Low Back Pain","Back Pain Lower Back","2026-06-16",{"date":58,"type":33},"2026-06-18",{"date":60,"type":33},"2026-06-02",{"date":62,"type":19},"2027-11-30",{"name":39,"class":40},1,""]